I-Mab up on completing enrollment for pediatric therapy study

NovaBridge Biosciences

31/05/2022 14:28

** U.S.-listed shares  IMAB.O  of drug developer I-Mab up
3.9% at $8.60 premarket
    ** Company completes enrollment in late-stage trial of its
experimental treatment, eftansomatropin alfa, which is being
conducted in China  urn:newsml:reuters.com:*:nPn8Df096a
    ** The trial is testing eftansomatropin alfa as a weekly
treatment for pediatric growth hormone deficiency
    ** I-Mab anticipates final data from the study in 2023
    ** Company's shares down 82.5% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))